Abstract
The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.
Original language | English (US) |
---|---|
Pages (from-to) | 2113-2115 |
Number of pages | 3 |
Journal | Cancer Treatment Reports |
Volume | 62 |
Issue number | 12 |
State | Published - Dec 1 1978 |
ASJC Scopus subject areas
- Oncology
- Cancer Research